Loading data for SRRK — first visit, this takes a few seconds.

Scholar Rock Holding Corporation (SRRK)

NasdaqGS: SRRK · Real-Time Price · USD

56.10

+0.21 (0.38%)

At close: Sep 02, 2026, 8:00 PM

55.96

-0.25%

Pre-market: 8:30 AM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	40.2
Market Cap	6.83B
Revenue (ttm)	n/a
Net Income (ttm)	-409M
	0.67
	-3.31
	n/a
	-24.09
P/B (ttm)	26.88
P/S (ttm)	0.00
Earnings Date	Nov 12, 2026

Ask	70.8
Volume	1,065,726
Avg. Volume (20D)	1,311,161
Open	56.62
Previous Close	55.89
Day's Range	55.27 - 58.09
52-Week Range	27.07 - 61.76
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 25, 2018

Employees 289

Stock Exchange NasdaqGS

Ticker Symbol SRRK

Website https://www.scholarrock.com

Full Company Profile

Financial Performance

In 2025, Scholar Rock's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -377.94M, an increase of 53.45%.

Financial Statements

Earnings Surprise

Scholar Rock has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.84 misses estimates by 0.00, with 14.29% YoY growth.

Next Earnings Release

Scholar Rock Holding Corporation is scheduled to release its earnings on Nov 12, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 weeks ago · Simply Wall St.

Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On Returns

Scholar Rock Holding stock has delivered an extremely strong multi year return, yet the latest valuation checks suggest the current share price may already be baking in a lot of optimism. After such a...

2 weeks ago · Simply Wall St.

Is Scholar Rock Holding (SRRK) Fairly Valued On Its Apitegromab Regulatory Progress?

Scholar Rock Holding (SRRK) updated investors after shifting apitegromab’s commercial fill finish work away from Catalent Indiana following FDA inspection issues, while confirming that the FDA is cont...

2 weeks ago · Simply Wall St.

Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story?

Earlier this week, Scholar Rock announced it has removed Catalent Indiana from all commercial fill-finish roles for apitegromab, with the FDA continuing to review its U.S. BLA using an alternate, prev...

2 weeks ago · Stocktwits

SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing

The company said it has, in accordance with FDA guidance, removed Catalent Indiana—a fill-finish plant now owned by Novo Nordisk—from its U.S. biologics license application for apitegromab.

2 weeks ago · MT Newswires

Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility

Scholar Rock (SRRK) said Friday that, under guidance from the FDA, it has removed Novo Nordisk's (NV

Page 1 of 2

Scholar Rock Holding Corporation (SRRK)